For instance, a recent study proposed that pazopanib induces DC activation by inhibiting the ß‐catenin pathway in vitro,62 with possible enhancement of T‐cell responses,63 while novel VEGF‐directed drugs, such as axitinib, increase the expression of NKG2D ligands in the tumor cells and consequently potentiate NK cell cytolytic activity.64 This evidence concerns the gene VEGFA and neoplasm.